Which manufacturer is Acotiamide?

The R&D and production of Acotiamide is led by Astellas Pharma Inc., a Japanese pharmaceutical company. Astellas Pharma is a leading global innovative pharmaceutical company focusing on the research and development of drugs in multiple fields including digestive diseases, oncology and renal diseases. The research and development background of acotiamide is based on in-depth research on the pathological mechanisms of functional dyspepsia, especially the regulatory effects of gastric motility disorders and abnormal acetylcholine signaling pathways.

As an original drug, the production of acotiamide strictly followsGMP standards to ensure drug purity, dosage accuracy and efficacy stability. The drug is provided in the form of sustained-release tablets, and the dosage of each tablet is standardized to facilitate clinical adjustment as needed. Astellas Pharma strictly manages storage, transportation and packaging to ensure that drugs maintain efficacy and safety during use. The development and marketing of acotiamide went through multi-stage clinical trials, which verified its clinical effect in relieving symptoms of functional dyspepsia and improving gastric motility, while ensuring tolerability and safety.

In the international market,Astellas Pharma supplies acotiamide through Japan and parts of Asia, providing reliable drug options for patients with functional dyspepsia. There is no domestic production or sales approval, and all regular supplies are provided by the company in overseas markets. If it is approved domestically in the future, it is expected to be produced and sold by Astellas Pharma or its authorized companies, continuing its professional advantages in the field of gastric motility treatment. With its innovative pharmacological mechanism and strict production quality management, acotiamide provides a highly safe and sustainable treatment plan for patients with functional dyspepsia, and also provides a reference for future domestic gastric motility drug research and development.

Reference: https://www.rad-ar.or.jp/siori/english/search/result?n=33322